Shares of Natera Inc (NASDAQ:NTRA) have earned a consensus recommendation of “Buy” from the eleven research firms that are presently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $46.00.

A number of brokerages recently commented on NTRA. Robert W. Baird increased their price target on shares of Natera from $40.00 to $42.00 and gave the company an “outperform” rating in a report on Thursday, May 7th. Zacks Investment Research downgraded shares of Natera from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. ValuEngine raised shares of Natera from a “hold” rating to a “buy” rating in a report on Wednesday, March 18th. JPMorgan Chase & Co. raised shares of Natera from a “neutral” rating to an “overweight” rating and increased their price target for the company from $32.00 to $45.00 in a report on Thursday, May 7th. Finally, Canaccord Genuity raised their price objective on shares of Natera from $46.00 to $48.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th.

In other news, CEO Steven Leonard Chapman sold 1,564 shares of the firm’s stock in a transaction that occurred on Friday, April 3rd. The shares were sold at an average price of $27.50, for a total transaction of $43,010.00. Following the transaction, the chief executive officer now directly owns 11,196 shares of the company’s stock, valued at $307,890. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Michael Burkes Brophy sold 10,021 shares of the firm’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $45.77, for a total transaction of $458,661.17. Following the transaction, the chief financial officer now directly owns 54,166 shares in the company, valued at $2,479,177.82. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 248,607 shares of company stock worth $10,806,115. Corporate insiders own 9.29% of the company’s stock.

A number of hedge funds have recently modified their holdings of the stock. Ameritas Investment Partners Inc. grew its holdings in Natera by 4.6% in the first quarter. Ameritas Investment Partners Inc. now owns 5,602 shares of the medical research company’s stock worth $167,000 after purchasing an additional 245 shares during the last quarter. US Bancorp DE grew its holdings in Natera by 31.8% in the first quarter. US Bancorp DE now owns 1,991 shares of the medical research company’s stock worth $60,000 after purchasing an additional 480 shares during the last quarter. Alliancebernstein L.P. grew its holdings in Natera by 0.7% in the fourth quarter. Alliancebernstein L.P. now owns 76,000 shares of the medical research company’s stock worth $2,560,000 after purchasing an additional 500 shares during the last quarter. Citigroup Inc. grew its holdings in Natera by 1.1% in the fourth quarter. Citigroup Inc. now owns 54,067 shares of the medical research company’s stock worth $1,821,000 after purchasing an additional 572 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its holdings in Natera by 4.7% in the first quarter. Nisa Investment Advisors LLC now owns 13,300 shares of the medical research company’s stock worth $397,000 after purchasing an additional 600 shares during the last quarter. 93.91% of the stock is currently owned by institutional investors.

Shares of NTRA traded up $2.16 during midday trading on Tuesday, hitting $49.86. 920,467 shares of the company traded hands, compared to its average volume of 953,275. The firm has a 50 day moving average of $44.42 and a 200-day moving average of $36.67. Natera has a 52 week low of $16.87 and a 52 week high of $49.97. The stock has a market cap of $3.75 billion, a price-to-earnings ratio of -28.99 and a beta of 1.37. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.73 and a current ratio of 2.81.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Wednesday, May 6th. The medical research company reported ($0.45) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.57) by $0.12. Natera had a negative net margin of 38.28% and a negative return on equity of 78.56%. The firm had revenue of $94.01 million during the quarter, compared to the consensus estimate of $85.02 million. During the same quarter last year, the firm earned ($0.54) EPS. The firm’s revenue for the quarter was up 40.7% compared to the same quarter last year. Sell-side analysts predict that Natera will post -2.14 earnings per share for the current fiscal year.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Read More: What does a bar chart display?

Analyst Recommendations for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.